Radionuclide-Drug Conjugates (RDCs)
Radionuclide-drug conjugates (RDCs) are one of the most promising development directions for nuclear drug targeted therapy. RDC is composed of targeting element, linker, chelate and radioactive isotope. RDC has advantages in early tumor diagnosis, treatment and postoperative tumor evaluation. The same ligand can be connected to nuclides used for disease diagnosis and treatment respectively, promoting the integration of diagnosis and treatment of RDC drugs. This entry provides molecular intermediates that can be used in the synthesis and research of RDC.
Radionuclide-Drug Conjugates (RDCs) Isoform Specific Products
All Product Categories
-
Radionuclide-Drug Conjugates (RDCs) Related Products (226)
Related Products (226)
-
Radionuclide-Drug Conjugates (RDCs) Isoform Comparison
-
Icopezil maleate
0 ImagesCat. No.: HY-105157ACAS No.: 145815-98-1Synonyms: CP-118954 maleateIcopezil maleate (CP-118954 maleate) is an orally active, selective AchE inhibitor with an IC50 of 0.33 nM. Icopezil maleate increases acetylcholine levels in the brain and striatum of mammals, induces centrally mediated tremors and peripherally mediated salivation, and improves working memory performance in aged dogs. Icopezil maleate serves as a parent compound for radioiodine-labeled acetylcholinesterase imaging agents. Icopezil maleate is applicable to research related to Alzheimer's disease.
-
Maleimide-DTPA TFA
0 ImagesCat. No.: HY-W738256APurity: 98.06%Synonyms: MDTPA TFAMaleimide-DTPA (MDTPA) TFA is a monoreactive DTPA derivative (MDTPA) with maleimide group as peptide binding site, which can be combined with radionuclides to prepare radionuclide conjugates (RDC). Maleimide-DTPA TFA can chelate indium-111 (111In) and label peptides and peptides with indium-111. For example, it has high stability when combined with OST7 incubated in human serum, which is better than cyclic cDTPA. Maleimide-DTPA TFA is a good material for medical imaging or treatment.
-
NOPO
0 ImagesCat. No.: HY-164589CAS No.: 1397275-76-1NOPO is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy.
-
VCAM1 binding peptide, FITC labeled acetate
0 ImagesCat. No.: HY-P11088FVCAM1 binding peptide, FITC labeled acetate is a FITC-labeled VCAM1 binding peptide acetate (HY-P11088A). VCAM1 binding peptide acetate is a VCAM1 binder with internalization activity. VCAM1 binding peptide acetate serves as a component of biosensing systems for visualizing in vitro VCAM1 endocytic pathways. VCAM1 binding peptide acetate forms the research and development basis for MacroP and NAMP, PET radiotracers targeting VCAM1. VCAM1 binding peptide acetate is applicable to studies related to atherosclerosis.
-
NOTP
0 ImagesCat. No.: HY-138134CAS No.: 83834-39-3NOTPis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NOTP can be used for conjugation of peptides and radionuclides.
-
GB-6
0 ImagesCat. No.: HY-P5520CAS No.: 2413262-74-3GB-6 is a short linear peptide that targets the gastrin releasing peptide receptor (GRPR). GRPR is overexpressed in pancreatic cancer. Based on the tumor selectivity and tumor-specific accumulation properties of GB-6, GB-6 labeled with near infrared (NIR) fluorescent dyes or radionuclide netium-99m (99mTc) can be used as a high-contrast imaging probe. GB-6 has excellent in vivo stability, with tumor to pancreatic and intestinal fluorescence signal ratios of 5.2 and 6.3, respectively, in SW199 0 subcutaneous xenograft models. GB-6 can rapidly target tumors and accurately delineate tumor boundaries, which has broad application prospects.
-
DOTA-PEG4-TFP
0 ImagesCat. No.: HY-167791CAS No.: 2389064-50-8DOTA-PEG4-TFP is a conjugate of the chelating agent DOTA (HY-W053583) and a linker. DOTA-PEG4-TFP can be used in the synthesis of radionuclide compounds.
-
DOTA-NT-20.3-IPBA
0 ImagesCat. No.: HY-P11845DOTA-NT-20.3-IPBA is a Neurotensin receptor 1 (NTR1)-targeting albumin binder with specific high-affinity binding to NTR1. DOTA-NT-20.3-IPBA is formed by the conjugation of DOTA-NT-20.3 and IPBA. DOTA-NT-20.3-IPBA can be used for positron emission tomography (PET) imaging following labeling with [68Ga]Ga.
-
SCN-PYTA
0 ImagesCat. No.: HY-183600SCN-PYTA is a bifunctional chelator for trivalent radiometals. After conjugation with monoclonal antibodies, SCN-PYTA forms a stable complex with 225Ac to achieve efficient radiolabeling. SCN-PYTA can be used in cancer research.
-
DOTA-cTMTP1
0 ImagesCat. No.: HY-P11816DOTA-cTMTP1 is a cyclic tumor-homing peptide precursor molecule. DOTA-cTMTP1 selectively binds to XPNPEP2 on highly metastatic tumor cells, accumulates and retains in hepatocellular carcinoma tumors, and maintains a high tumor-to-liver contrast over time in small animal models. After radiolabeling with 68Ga, DOTA-cTMTP1 forms a PET probe for positron emission tomography (PET) imaging of hepatocellular carcinoma (HCC).
-
NODAGA-NHS
0 ImagesCat. No.: HY-156991CAS No.: 1407166-70-4Synonyms: NODA-GA-NHS esterNODAGA-NHS (NODA-GA-NHS ester) is the activated ester form of the NODAGA chelator. NODAGA-NHS conjugates with Trastuzumab (HY-P9907) to form NODAGA-Trastuzumab, a conjugate that can chelate 64Cu for the preparation of radiotracers. NODAGA-NHS covalently binds to the amino group of lactosamine derivatives to form radiotracer precursors. [64Cu]NODAGA-trastuzumab enables PET imaging of tumors expressing HER2. NODAGA-NHS is used in studies of HER2-positive breast cancer and ovarian adenocarcinoma.
-
TRAP
0 ImagesCat. No.: HY-W873634CAS No.: 1242003-07-1Synonyms: TRAP-PrTRAP-Pr is a radionuclide conjugate (RDC) that can bind to the radionuclide [68]Ga. RDCs have the ability to specifically target biomolecules and can be used in medical imaging or therapy. TRAP-Pr can be further functionalized with acetone and used in click chemistry CuAAC reactions to conjugate other labeled molecules.
-
PTP peptide
0 ImagesCat. No.: HY-P11850CAS No.: 1192023-11-2PTP peptide is a specific Plectin-1 binder. PTP peptide can serve as a component of imaging agents; when conjugated with magnetofluorescent nanoparticles, it enables the detection of small pancreatic ductal adenocarcinomas and precancerous lesions via in vivo confocal microscopy and MRI. When conjugated with imaging agents, PTP peptide specifically targets pancreatic ductal adenocarcinoma cells, and can be used for tumor visualization and compound delivery. PTP peptide is applicable to research related to pancreatic ductal adenocarcinoma.
-
MIP-1072
0 ImagesCat. No.: HY-129615CAS No.: 949575-20-6MIP-1072 is a competitive prostate-specific membrane antigen (PSMA) inhibitor with a Ki value of 4.6 nM. MIP-1072 specifically binds to PSMA and is internalized into PSMA-expressing prostate cancer cells. MIP-1072 accumulates in PSMA-expressing prostate cancer xenografts. MIP-1072 specifically blocks the uptake of 68Ga-NOTA-GUL by PSMA-positive prostate cancer xenografts. When radiolabeled with 123I, MIP-1072 functions as a SPECT/CT molecular imaging agent. MIP-1072 can be used in prostate cancer-related research.
-
DOTA-CXCR4-L
0 ImagesCat. No.: HY-P5297DOTA-CXCR4-L is a CXCR4 targeting peptide. DOTA-CXCR4-L can be used in the study of cancers, including glioblastoma and triple-negative breast cancer. NODAGA-LM3 can be labeled with [68Ga]/[177Lu] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
-
ProX1-(SS)-DOTAGA_R
0 ImagesCat. No.: HY-185120CAS No.: 3084147-79-2ProX1-(SS)-DOTAGA_R (Compound 25a) is the unbound radionuclide portion of the radiopharmaceutical and can be used for targeted delivery to diseases characterized by ACP3 expression.
-
NO2A-Butyne-bis(t-Butyl ester)
0 ImagesCat. No.: HY-W749614CAS No.: 2125661-91-6NO2A-Butyne-bis(t-Butyl ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NO2A-Butyne-bis(t-Butyl ester) can be used for conjugation of peptides and radionuclides.
